Mexico Johnes Disease Diagnostic Market Size & Outlook, 2026-2034
Mexico Johnes Disease Diagnostic Market Insights
- As per Reed Intelligence insights, the Mexico Johnes Disease Diagnostic Market stood at USD 3.01 Million in 2025 and is anticipated to grow to USD 5.56 Million by 2034.
- The Mexico market is expected to advance at a CAGR of 6.99% from 2026 through 2034.
- In 2025, ELISA-Based Tests accounted for the highest share of the By Test Type market size.
- During the forecast period, ELISA-Based Tests is set to register the highest growth, making it the most lucrative By Test Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2025, Mexico held 1.43% of the global Johnes Disease Diagnostic Market size.
- By 2034, United States is anticipated to capture the largest share of the global Johnes Disease Diagnostic Market.
- In LATAM, Brazil is expected to lead the regional Johnes Disease Diagnostic Market size by 2034.
- Colombia will remain the fastest-growing market in LATAM, reaching USD 1.48 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 3.01 Million |
| Market Size In 2034 | USD 5.56 Million |
| Largest segment | ELISA-Based Tests |
| Units | Revenue in USD Million |
| CAGR | 6.99% (2026-2034) |
| Segmnetation Covered | |
| By Test Type |
|
| By Sample Type |
|
| By End-Use |
|
| By Distribution Channel |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Mexico Johnes Disease Diagnostic Market By Test Type 2026-2034 (USD Million)
| By Test Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELISA-Based Tests | XX.x | XX.x | XX.x | 1.54 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| PCR-Based Diagnostics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Culture-Based Methods | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Mexico Johnes Disease Diagnostic Market By Sample Type 2026-2034 (USD Million)
| By Sample Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood Samples | XX.x | XX.x | XX.x | 1.42 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Fecal Samples | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Tissue Samples | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Mexico Johnes Disease Diagnostic Market By End-Use 2026-2034 (USD Million)
| By End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veterinary Laboratories | XX.x | XX.x | XX.x | 1.39 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Farms | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Mexico Johnes Disease Diagnostic Market By Distribution Channel 2026-2034 (USD Million)
| By Distribution Channel | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Direct Sales | XX.x | XX.x | XX.x | 1.39 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Distributors | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Online Sales | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.